Abstract
Third‐generation beta‐blocking agents developed for the hypertension market are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta‐adrenergic withdrawal produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both β1 and β2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second‐generation, β1‐selective compounds. For this and potentially other reasons, third‐generation beta‐blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large‐scale trials. Ongoing trials with either second‐ or third‐generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third‐generation compounds have an advantage in the treatment of chronic HF.
Keywords: adrenergic nervous system, heart failure, beta‐blocking agents, third‐generation beta‐blocking agents
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
References
- 1. Eichhorn EJ, Bristow MR: Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 1996; 94: 2285–2296 [DOI] [PubMed] [Google Scholar]
- 2. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–1552 [DOI] [PubMed] [Google Scholar]
- 3. Packer M, Carver JR, Chesebro JH, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE investigators : Effect of milrinone on mortality in severe chronic heart failure. The prospective randomized milrinone survival evaluation (PROMISE). N Engl J Med 1991; 325: 1468–1475 [DOI] [PubMed] [Google Scholar]
- 4. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA, for the Enoximone Multi‐center Trial Group : Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990; 82: 774–780 [DOI] [PubMed] [Google Scholar]
- 5. Feldman A, Young J, Bourge R, Carson P, Jaski B, DeMets D, White BG, Cohn JN, for the VesT Investigators : Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VesT). J Am Coll Cardiol 1997; 29: 64A [Google Scholar]
- 6. Packer M, Francis GS, Abrams J, Cobb FR, Eichhorn EJ, Giles TD, Kahl FR, Tandon PK: Oral milrinone increases the risk of sudden death in severe chronic heart failure: The PROMISE trial. Circulation 1991; 84: II–310 [Google Scholar]
- 7. Eichhorn EJ, Bristow MR: Practical guidelines for initiation of β‐adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794–798 [DOI] [PubMed] [Google Scholar]
- 8. Bristow MR: Mechanism of action of beta‐blocking agents in heart failure. Am J Cardiol 1997; 80: (11A): 26L–40L [DOI] [PubMed] [Google Scholar]
- 9. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM: β‐adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82:(suppl I)12‐25 [PubMed] [Google Scholar]
- 10. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree, J , Verhaegen H, Reneman RS, Janssen PAJ: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1‐adrenergic antagonist. J Cardiovasc Pharmacol 1998; 11 (5): 552–563 [DOI] [PubMed] [Google Scholar]
- 11. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR: Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17 (suppl B): 8–16 [DOI] [PubMed] [Google Scholar]
- 12. Louis WJ, Drummer OH, Tung L‐H: Actions of dilevalol on adren‐oceptors. J Cardiovasc Pharmacol 1988; 11 (suppl 2): 5–11 [DOI] [PubMed] [Google Scholar]
- 13. Rimele TJ, Aarhus LL, Lorenz RR, Rooke TW, Vanhoutte PM: Pharmacology of bucindolol in isolated canine vascular smooth muscle. J Pharmacol Exp Therap 1984; 231 (12): 317–325 [PubMed] [Google Scholar]
- 14. Hershberger RE, Wynn JR, Sundberg L, Bristow MR: Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990; 15: 959–967 [DOI] [PubMed] [Google Scholar]
- 15. Blin N, Camoin L, Maigret B, Strosberg D: Structural and conformational features determining selective signal transduction in the β3‐adrenergic receptor. Mol Pharmacol 1993; 44: 1094–1104 [PubMed] [Google Scholar]
- 16. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CPL‐H, Dupont AG, VanNueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: Evidence for an L‐arginine/No‐dependent mechanism. J Pharmacol Exp Therap 1995; 274: 1067–1071 [PubMed] [Google Scholar]
- 17. Tung LH, Jackman G, Campbell B, Louis S, Iakovidis D, Louis WJ: Partial agonist activity of celiprolol. J Cardiovasc Pharmacol 1993; 21: 484–488 [DOI] [PubMed] [Google Scholar]
- 18. Jasper JR, Michel MC, Insel PA: Amplification of cyclic AMP generation reveals agonistic effects of certain β‐adrenergic antagonists. Mol Pharmacol 1989; 37: 44–49 [PubMed] [Google Scholar]
- 19. Böhm M, Schulz C, Schwinger RHG, Erdmann E: Positive inotropic effects due to partial agonistic activity of the β‐adreno‐ceptor antagonist celiprolol following amplification of cAMP formation in failing human myocardium. J Cardiovasc Pharmacol 1992; 20: 479–489 [DOI] [PubMed] [Google Scholar]
- 20. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in heart failure: A double‐blind randomized study. J Am Coll Cardiol 1995; 25: 1225–1231 [DOI] [PubMed] [Google Scholar]
- 21. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817–2825 [DOI] [PubMed] [Google Scholar]
- 22. Yue T‐L, Cheng H‐Y, Lysko PG, McKenna PJ, Feurstein R, Gu J‐L, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta‐adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Therap 1992; 263: 92–98 [PubMed] [Google Scholar]
- 23. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Müller‐Beckmann B: Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992; 19 (suppl 1): 68–80 [DOI] [PubMed] [Google Scholar]
- 24. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators : Dose‐response of chronic β‐blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89: 1632–1642 [DOI] [PubMed] [Google Scholar]
- 25. Deitchman D, Perhach JL, Snyder RW: β‐adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharm 1980; 61: 263–277 [DOI] [PubMed] [Google Scholar]
- 26. Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR: Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology 1998; 56: 30–36 [DOI] [PubMed] [Google Scholar]
- 27. Focaccio A, Larrabee P, Wollmering MM, Bristow MR: Xamoterol has agonist activity in end‐stage failing human heart. J Am Coll Cardiol 1991; 17: 250A [Google Scholar]
- 28. Wollmering MM, Wiechmann RJ, Port JD, Hershberger RE, Focaccio A, Bristow MR: Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. J Am Coll Cardiol 1991; 17: 283A [Google Scholar]
- 29. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990; 336: 1–6 [PubMed] [Google Scholar]
- 30. Silke B, Guy S, Riddell JG: Effects of β‐adrenoceptor agonists and antagonists on heart‐rate variability in normal subjects assessed using summary statistics and nonlinear procedures. J Cardiovasc Pharmacol 1997; 30: 817–823 [DOI] [PubMed] [Google Scholar]
- 31. Parati G, Ravogli A, Bragato R, Omboni S, Mutti E, Mancia G: Clinical and hemodynamic effects of celiprolol in essential hypertension. J Cardiovasc Pharmacol 1989; 14 (suppl 7): 14–21 [PubMed] [Google Scholar]
- 32. Chidiac P, Herbert TE, Valiquette M, Dennis M, Bouvier M: Inverse agonist activity of β‐adrenergic antagonists. Mol Pharmacol 1993; 45: 490–499 [PubMed] [Google Scholar]
- 33. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ: Negative antagonists promote an inactive conformation of the β2‐adrenergic receptor. Mol Pharmacol 1993; 45: 390–394 [PubMed] [Google Scholar]
- 34. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR: Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β‐adrenergic receptor blocking agents. Circulation 1994; 90 (4): I–543 [Google Scholar]
- 35. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators : Carvedilol produces dose‐related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–2816 [DOI] [PubMed] [Google Scholar]
- 36. Packer M, Bristow MR, Colin JN, Colucci WS, Fowler MB, Gilhen EM, Shusterman NH: Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355 [DOI] [PubMed] [Google Scholar]
- 37. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ: Enhanced myocardial function in transgenic mice overexpressing the β‐adrenergic receptor. Science 1994; 264: 582–586 [DOI] [PubMed] [Google Scholar]
- 38. Haber HL, Christopher LS, Gimple LW, Bergin JD, Subbiah ME, Jayaweera AR, Powers ER, Feldman MD: Why do patients with congestive heart failure tolerate the initiation of β‐blocker therapy? Circulation 1993; 88: 1610–1619 [DOI] [PubMed] [Google Scholar]
- 39. Talwar KK, Bhargava B, Upasani PT, Verma S, Kamlakar T, Chopra P: Hemodynamic predictors of early intolerance and long‐temi effects of propranolol in dilated cardiomyopathy. J Cardiac Failure 1996; 2 (4): 273–277 [DOI] [PubMed] [Google Scholar]
- 40. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA: Effect of beta‐adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990; 82: 473–483 [DOI] [PubMed] [Google Scholar]
- 41. Wisenbaugh T, Kalz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P: Long‐term (3 month) effects of a new beta‐blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21; 1094–1100 [DOI] [PubMed] [Google Scholar]
- 42. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Pass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR: Effect of metoprolol on myocardial function and energetics in patients with non‐ischemic dilated cardiomyopathy: A randomized, double‐blind, placebo‐controlled study. J Am Coll Cardiol 1994; 24: 1310–1320 [DOI] [PubMed] [Google Scholar]
- 43. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta‐adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–1036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR: Chronic β‐blocker‐vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double‐blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223–229 [DOI] [PubMed] [Google Scholar]
- 45. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR: Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998; 81: 247–250 [DOI] [PubMed] [Google Scholar]
- 46. Anderson JL, Gilbert EM, O'Connell JB. Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, Bristow M: Long‐term (2 year) beneficial effects of beta‐adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991; 17: 1373–1381 [DOI] [PubMed] [Google Scholar]
- 47. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group : Beneficial effects of metoprolol in idiopathic dilated cardiomyopalhy. Lancet 1993; 342: 1441–1446 [DOI] [PubMed] [Google Scholar]
- 48. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Adverse effects of beta‐blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980; 44: 134–142 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ: Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995; 75: 360–364 [DOI] [PubMed] [Google Scholar]
- 50. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM: Second‐ and third‐generation beta‐blocking drugs in chronic heart failure. Cardiovasc Druts Ther 1997; 11: 291–296 [DOI] [PubMed] [Google Scholar]
- 51. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR: Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996; 78: 779–784 [DOI] [PubMed] [Google Scholar]
- 52. Doughty RN, Whalley GA, Gamble G, Mac Mahon S, Sharpe N, on behalf of the Australia‐New Zealand Heart Failure Research Collaborative Group : Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997; 29: 1060–1066 [DOI] [PubMed] [Google Scholar]
- 53. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ: Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β‐adrenergie blockade. J Am Coll Cardiol 1995; 25: 1154–1161 [DOI] [PubMed] [Google Scholar]
- 54. Lowes BD, Gill EA, Abraham WT, Larrabee JR, Robertson AD, Bristow MR, Gilbert EM: The effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol, in press [DOI] [PubMed]
- 55. Anderson B, Caidahl K, diLenarda A, Warren SE, Goss F, Waldenström A, Persson S, Wallentin I, Hjalmarson Å, Waagstein F: Changes in early and late diastolic tilling patterns induced by longterm adrenergic β‐blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 673–682 [DOI] [PubMed] [Google Scholar]
- 56. Bristow MR, Port JD: β‐adrenergic blockade in chronic heart failure. Scand Cardiovasc J 1998; 47: 45–55 [DOI] [PubMed] [Google Scholar]
- 57. Australia‐New Zealand Heart Failure Research Collaborative Group : Effects of carvedilol, a vasodilator‐β‐blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995; 92: 212–218 [PubMed] [Google Scholar]
- 58. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B, for the SOLVD Investigators : Effects of long‐term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573–2581 [DOI] [PubMed] [Google Scholar]
- 59. Cohn JN: Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504–2507 [DOI] [PubMed] [Google Scholar]
- 60. Packer M, Colucci WS, Sackner‐Bernstein JD, Liang C‐S, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowilz NN, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group : Double‐blind, placebo‐controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation 1996; 94: 2793–2799 [DOI] [PubMed] [Google Scholar]
- 61. Krum H, Sakner‐Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Kate SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double‐blind, placebocontrolled study of the long‐term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92: 1499–1506 [DOI] [PubMed] [Google Scholar]
- 62. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA: Safety and efficacy of carvedilol in severe heart failure. J Cardiac Failure 1997; 3: 173–179 [DOI] [PubMed] [Google Scholar]
- 63. Bristow MR, Hershberger RE, Port JD, Rasmussen R: β1 and β2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989; 35: 295–303 [PubMed] [Google Scholar]
- 64. Green SA, Holt BD, Liggett SB: β1 ‐and β2‐adrenergic receptors display subtype‐selective coupling to Gs . Mol Phamacol 1992: 41: 889–893 [PubMed] [Google Scholar]
- 65. Lubbe WF, Podzuweit T, Opie LH: Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta‐blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992; 19 (7): 1622–1633 [DOI] [PubMed] [Google Scholar]
- 66. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Bristow MR: β‐blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426–2441 [DOI] [PubMed] [Google Scholar]
- 67. Lowes BD, Abraham, WT , Dutcher, DL , Roden RL, Crisman TS, Minobe W, Port JD, Larrabee P, Gilbert EM, Bristow MR: Comparative anti‐adrenergic effects of carvedilol and metoprolol in a randomized, placebo‐controlled‐trial. Circulation 1996; 94 (suppl); I–664 [Google Scholar]
- 68. Corr PB, Witkowski FX: Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion on ischemic myocardium. Circulation 1983; 68 (suppl I); 16–24 [PubMed] [Google Scholar]
- 69. CIBIS Investigators : A randomized trial of beta‐blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90: 1765–1773 [DOI] [PubMed] [Google Scholar]
- 70. Fagerberg B: The International Steering Committee on behalf of the MERIT‐HF Study Group: Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERiT‐HF). Am J Cardiol 1997; 80 (9B); 54–58 [DOI] [PubMed] [Google Scholar]
- 71. The BEST Steering Committee : Design of the Beta‐Blocker Evaluation Survival Trial (BEST) Am. J Cardiol 1995; 75: 1220–1223 [DOI] [PubMed] [Google Scholar]
- 72. Metra M, Nardi M, Giubbini R, Cas LD: Effects of short‐ and longterm carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24 (7); 1678–1687 [DOI] [PubMed] [Google Scholar]
- 73. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner‐Bernstein JD, Young ST, Holcslaw TL, Lukas MA: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800–2806 [DOI] [PubMed] [Google Scholar]
- 74. Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L: Nebivolol in the treatment of cardiac failure: A doubleblind controlled clinical trial. J Cardiac Failure 1997; 3 (4): 271–276 [DOI] [PubMed] [Google Scholar]
- 75. Waagstein F, Caidahl K, Wallentin I, Bergh C‐H, Hjalmarson A: Long‐term β‐blockade in dilated cardiomyopathy: Effects of shortand long‐term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551–563 [DOI] [PubMed] [Google Scholar]
- 76. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol 1994; 23 (4); 943–950 [DOI] [PubMed] [Google Scholar]